Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight ratings firms that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $52.33.

Several research firms have weighed in on AGIO. Leerink Partnrs cut Agios Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, September 27th. StockNews.com upgraded Agios Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, November 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Agios Pharmaceuticals in a research report on Friday, September 20th. Raymond James reissued an "outperform" rating and issued a $51.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st.

Agios Pharmaceuticals Trading Down 2.9 %

Agios Pharmaceuticals stock traded down $1.62 during trading hours on Friday, reaching $53.78. 926,800 shares of the stock were exchanged, compared to its average volume of 704,416. Agios Pharmaceuticals has a twelve month low of $20.96 and a twelve month high of $62.58. The company has a market cap of $3.07 billion, a P/E ratio of 4.73 and a beta of 0.75. The stock has a 50 day moving average of $46.44 and a two-hundred day moving average of $43.87.

Insider Buying and Selling at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company's stock, valued at approximately $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.93% of the company's stock.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals during the 2nd quarter worth about $37,000. Quest Partners LLC bought a new stake in shares of Agios Pharmaceuticals during the 2nd quarter valued at about $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company's stock worth $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC lifted its stake in Agios Pharmaceuticals by 554.7% in the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 1,836 shares during the period. Finally, Quantbot Technologies LP bought a new position in shares of Agios Pharmaceuticals during the 3rd quarter worth approximately $146,000.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.